Sanctuary Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$986K Buy
3,996
+857
+27% +$218K ﹤0.01% 1538
2026
Q2
$945K Sell
3,139
-2,700
-46% -$814K ﹤0.01% 1489
2026
Q1
$1.93M Sell
5,839
-681
-10% -$232K 0.01% 973
2025
Q4
$2.59M Buy
6,520
+345
+6% +$153K 0.01% 792
2025
Q3
$2.82M Buy
6,175
+2,103
+52% +$856K 0.02% 733
2025
Q2
$1.33M Buy
4,072
+782
+24% +$216K 0.01% 1054
2025
Q1
$888K Sell
3,290
-1,625
-33% -$418K 0.01% 1188
2024
Q4
$1.36M Buy
4,915
+357
+8% +$93.9K 0.01% 1074
2024
Q3
$1.12M Buy
4,558
+2,181
+92% +$568K 0.01% 1195
2024
Q2
$341K Buy
+2,377
New +$375K ﹤0.01% 1889

Other funds holding ALNY

Sanctuary Advisors's ALNY Position: Q3 2026 in Review

Sanctuary Advisors increased its Alnylam Pharmaceuticals (ALNY) stake by 27% in Q3 2026, buying an estimated $218K and bringing the position to 3,996 shares worth $986K. The position accounts for ﹤0.01% of the portfolio, ranked #1538.

Sanctuary Advisors first reported a position in ALNY in Q2 2024 and has held it in 10 quarters since. The position peaked at $2.82M in Q3 2025. 730 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

  • Sanctuary Advisors held 3,996 shares of Alnylam Pharmaceuticals worth $986K as of Q3 2026.
  • Sanctuary Advisors bought 857 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $218K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Sanctuary Advisors's portfolio in Q3 2026, its #1538 holding.
  • Sanctuary Advisors first reported a position in Alnylam Pharmaceuticals in Q2 2024 and has held it in 10 quarters since.
  • Sanctuary Advisors's Alnylam Pharmaceuticals position peaked at $2.82M in Q3 2025.
  • 730 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on Sanctuary Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.